

## SUPPLEMENTARY.

**Table S4. Post hoc comparisons of the baseline Clinical Global Impression scale, the 4-Items Negative Symptoms Assessment scale, and the Personal and Social Performance scores between the three paliperidone groups**

Symptoms	Dosage form	Symptoms	Dosage form	Mean Difference	SE	df	t	p	P <sub>tukey</sub>	P <sub>bonferroni</sub>
CGI-S										
Visit 1	OP	Visit 1	PP1M	-0.2917	0.1838	62.0	-1.5871	0.118	0.955	1.000
		Visit 1	PP3M	-0.2759	0.1784	62.0	-1.5462	0.127	0.964	1.000
Visit 1	PP1M	Visit 1	PP3M	0.0158	0.1434	62.0	0.1102	0.913	1.000	1.000
NSA-4										
Visit 1	OP	Visit 1	PP1M	-0.5761	1.596	62.0	-0.3610	0.719	1.000	1.000
		Visit 1	PP3M	-2.3500	1.530	62.0	-1.5355	0.130	0.966	1.000
Visit 1	PP1M	Visit 1	PP3M	-1.7739	1.242	62.0	-1.4285	0.158	0.981	1.000
PSP										
Visit 1	OP	Visit 1	PP1M	0.9170	3.467	62.0	0.2644	0.792	1.000	1.000
		Visit 1	PP3M	0.8049	3.366	62.0	0.2391	0.812	1.000	1.000
Visit 1	PP1M	Visit 1	PP3M	-0.1120	2.706	62.0	-0.0414	0.967	1.000	1.000

Note: df — the degrees of freedom; p — the significance level (p-value); OP — oral paliperidone; PP1M — paliperidone palmitate once a month; PP3M — paliperidone palmitate once every three months; CGI-S — the Clinical Global Impression scale; NSA-4 — the 4-Items Negative Symptoms Assessment scale; PSP — the Personal and Social Performance scale.